FDA plans up­com­ing ad­comms for OTC con­tra­cep­tive, ep­i­neph­rine nasal spray, Intar­ci­a's last shot

The FDA has sched­uled or planned for three ad­vi­so­ry com­mit­tee meet­ings in May: one for an over-the-counter birth con­trol pill, one for a nasal spray ver­sion of the EpiPen, and an­oth­er for  Intar­cia Ther­a­peu­tics, which has all but com­plete­ly fold­ed al­ready as a com­pa­ny.

Per­ri­go will bring its dai­ly con­tra­cep­tive, Opill, to the joint Non­pre­scrip­tion Drugs Ad­vi­so­ry Com­mit­tee and the Ob­stet­rics, Re­pro­duc­tive and Uro­log­ic Drugs Ad­vi­so­ry Com­mit­tee on May 9 and 10 for its over-the-counter birth con­trol ap­pli­ca­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.